Lipoprotein-associated phospholipase A2 and risk stratification for cardiovascular disease: Not ready for "prime time"

Mayo Clinic Proceedings

Volumn 82, Issue 2, 2007, Pages 155-157

  Steinberg, Daniel I ^a   Mayer, Alexander ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INTERLEUKIN 6; LIPOPROTEIN; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PLASMINOGEN; PYRIDOXINE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE MARKER; EDITORIAL; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; RISK FACTOR;

EID: 33846705338     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.2.155     Document Type: Editorial

References (10)

1. Thom T, Haase N, Rosamond W, et al, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 Feb 14;113;e85-e151.Epub 2006 Jan 11.
2. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377-381.
3. 2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159-165.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337:356]. N Engl J Med. 1997;336:973-979.
5. Berliner J, Leitinger N, Watson A, Huber J, Fogelman A, Navab M. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost. 1997;78:195-199.
6. Page J, Attia J. Using Bayes' nomogram to help interpret odds ratios. ACP J Club Sep-Oct 2003;139:A11-A12.
7. Danesh J, Wheeler JG, Hirshfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
8. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
9. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 2006;166:1368-1373
10. Topol EJ. Nesiritide - not verified. N Engl J Med. 2005;353:113-116.